Dan Med J 2013; 60 (2): A4575

2 danish mEdical JOURnal Dan Med J 60/2 February 2013 diagnosed after transurethral prostatectomy were included following re-biopsy, and the post-transurethral prostatectomy PSA-value was used as entry PSA. Patients were followed with digital rectal examination and PSA-tests every three months; and re-biopsies were offered after one year on active surveillance. The risk of progression was hereafter classified according to a modification of criteria originally proposed by Choo et al [10] and patients were managed as outlined in Table 1.

The PSA doubling time was calculated according to the Memorial Sloan-Kettering Cancer Center guidelines including all available PSA-values. Kaplan-Meier survival analysis was used to estimate the probability of remaining on active surveillance. Data are presented as median and range unless otherwise in-